Not a good buy right now for an impatient entry: price is stretched (RSI-6 ~86 overbought) and sits near resistance (R1 ~10.75), increasing near-term pullback risk.
Short-term pattern model also skews bearish (estimated next-day -2.29% / next-month -3.51%), which clashes with chasing strength.
While longer-term trend is improving (bullish moving averages) and Wall Street sentiment has turned more constructive, recent negative catalyst risk (product recall) + weak latest quarter growth make the current level a low-quality entry.
Intellectia Proprietary Trading Signals: no active buy signal today (neither AI Stock Picker nor SwingMax), so there’s no system-driven reason to force an entry now.
Politicians/Congress: no recent congress trading data available; insiders are neutral.
Technical Analysis
Trend: Bullish structure with SMA_5 > SMA_20 > SMA_200, suggesting an ongoing uptrend/turnaround attempt.
Momentum: RSI_6 = 86.475 (overbought) → elevated probability of a near-term dip or consolidation.
MACD: Histogram -0.0136 (below zero) but negatively contracting → downside momentum is fading, yet not fully flipped bullish.
Levels: Pivot 10.259; Support S1 9.766 (then S2 9.462). Resistance R1 10.752 (then R2 11.056). With price ~10.62, upside is close to resistance while downside room to support is larger.
Quant/pattern read: Similar-pattern study implies higher odds of near-term weakness (next day and next month).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Open interest put/call ratio 0.49 indicates more call open interest than puts (generally bullish/optimistic positioning).
Flow: Put volume is almost nonexistent (put/call volume ratio 0.0) with call volume dominating; today’s option volume is far above 30-day average (~217%).
Volatility: 30D IV 42.63 with very low IV percentile (9.16) / IV rank (~11.34) → options are relatively “cheap” vs recent history, often seen when fear is muted.
Takeaway: Options sentiment leans bullish, but it also raises the risk of a “crowded call” setup near resistance if spot pulls back.
Technical Summary
Sell
5
Buy
9
Positive Catalysts
Hedge funds are reported as net buyers with a sharp quarter-over-quarter increase in buying activity.
Recent execution signals from analysts: Guggenheim cited revenue/EBITDA beat and raised guidance; cost actions “starting to take hold.”
Technical trend structure (moving averages) supports an improving medium-term setup if the stock can consolidate above the pivot (~10.26).
Neutral/Negative Catalysts
Event-driven: Voluntary recall of HYCOAT Hyaluronate Sodium Sterile Solution due to microbial contamination risk; headline risk and potential financial/brand impact may linger.
Stock reaction to recall was negative (reported drop to ~$10.06 on announcement), showing sensitivity to quality/regulatory news.
Overbought technical condition (RSI) near resistance increases the odds that bad/uncertain news triggers a sharper pullback.
Financial Performance
Latest quarter: 2026/Q2.
Revenue: 224.691M, down -2.84% YoY (top-line contraction).
Profitability: Net income -15.924M (down -96.51% YoY) and EPS -0.07 (down -96.67% YoY) → earnings trend deteriorated.
Margins: Gross margin 37.29%, down -3.89% YoY → pressure on core economics.
Overall: Financial momentum is not yet supportive of paying up after a run; this reinforces a “wait for a pullback” stance rather than buying immediately.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Trend: Analyst tone has improved recently.
2025-12-10: CJS Securities upgraded to Outperform with $10 PT.
2026-01-09: Guggenheim kept Buy and raised PT to $12 from $8 after a beat and higher guidance.
Wall Street pros: improving execution, guidance raise, and cost actions gaining traction.
Wall Street cons: one quarter may not establish a durable trend; recent product recall adds uncertainty; fundamentals in the latest quarter still show YoY declines.
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NEOG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NEOG is 8.17 USD with a low forecast of 6.5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 10.590
Low
6.5
Averages
8.17
High
10
Current: 10.590
Low
6.5
Averages
8.17
High
10
Guggenheim
Buy
maintain
$8 -> $12
AI Analysis
2026-01-09
Reason
Guggenheim
Price Target
$8 -> $12
AI Analysis
2026-01-09
maintain
Buy
Reason
Guggenheim raised the firm's price target on Neogen to $12 from $8 and keeps a Buy rating on the shares after the company beat revenue and EBITDA expectations and raised guidance. While stating that one quarter "does not make a trend," the firm adds that the portfolio performed well and cost actions "clearly are starting to take hold."
CJS Securities
Robert Labick
Market Perform -> Outperform
upgrade
$10
2025-12-10
Reason
CJS Securities
Robert Labick
Price Target
$10
2025-12-10
upgrade
Market Perform -> Outperform
Reason
CJS Securities analyst Robert Labick upgraded Neogen to Outperform from Market Perform with a $10 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NEOG
